---
title: "Surrozen submits FDA IND for SZN-8141 in diabetic macular edema"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298320376.md"
description: "Surrozen Inc. has submitted an Investigational New Drug (IND) application to the FDA for SZN-8141, a treatment for diabetic macular edema. The company plans to initiate clinical testing with its DUET Phase 1b/2a trial expected to begin by the end of 2026. Initial data from this trial is targeted for release in the second half of 2027."
datetime: "2026-09-08T12:34:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298320376.md)
  - [en](https://longbridge.com/en/news/298320376.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298320376.md)
generator: "portal-rs"
---

# Surrozen submits FDA IND for SZN-8141 in diabetic macular edema

-   Surrozen submitted an IND application to the FDA to begin clinical testing of SZN-8141 for diabetic macular edema. \* DUET Phase 1b/2a trial expected to start by year-end 2026; initial data targeted for H2 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Surrozen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080830PRIMZONEFULLFEED9822467) on September 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [SRZN.US](https://longbridge.com/en/quote/SRZN.US.md)
- [SRZNW.US](https://longbridge.com/en/quote/SRZNW.US.md)

## Related News & Research

- [Surrozen says FDA clears IND for SZN-8141 diabetic macular edema trial](https://longbridge.com/en/news/300788834.md)
- [SRZN: Lead dual-mechanism therapy SZN-8141 enters trials, targeting major unmet needs in retinal disease](https://longbridge.com/en/news/299223813.md)
- [Elevance Health (ELV) Stock Still Looks Reasonable Despite Its 12% Gain](https://longbridge.com/en/news/300858530.md)
- [Western Digital vs. Sandisk: The Better Way to Play the Hard-Drive Side of the AI Storage Boom](https://longbridge.com/en/news/300870855.md)
- [Board Shake Up Might Change The Case For Investing In Asana (ASAN)](https://longbridge.com/en/news/300858613.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**